UK and Japan Partner to Fast-Track Genomic Medicine

Two countries are joining forces to revolutionize how doctors diagnose and treat disease, and patients in Japan could see the benefits within months.

Oxford Nanopore Technologies from the UK and A.D.A.M. Innovations, one of Japan's top genetic testing companies, signed a partnership agreement at the British Embassy in Tokyo this week. Their mission is simple but powerful: make genomic testing faster, more accurate, and available to more people.

The collaboration will bring Oxford Nanopore's real-time DNA sequencing technology into Japanese hospitals and clinics. Unlike existing methods, this technology can read DNA fragments of any length, capturing complete genetic information that traditional tests might miss. That means doctors could catch diseases earlier and prescribe treatments tailored to each patient's unique genetic makeup.

A.D.A.M. Innovations has already conducted nearly 3 million genetic tests and maintains the largest database of Japanese genetic information for research. Now they'll be able to offer even more comprehensive testing across multiple disease areas, from cancer to rare genetic conditions.

The partnership grew out of a 2024 health cooperation agreement between the UK and Japanese governments. Ambassador Julia Longbottom celebrated the deal as proof that international collaboration can deliver real benefits for patients, not just political talking points.

"This isn't just about sharing technology," said Gretchen Weightman from Oxford Nanopore. "We're creating clinical pathways that will help patients get answers faster."

The Ripple Effect spreads beyond Japan's borders. This collaboration strengthens ties between two of the world's leading life sciences hubs and creates a model for how countries can work together to advance medical care. Oxford Nanopore's technology is already used in over 125 countries to study everything from human diseases to environmental biology.

For Japan specifically, the partnership supports the country's focus on earlier and more precise diagnosis. Michel Mommejat, President of A.D.A.M. Innovations, emphasized that nanopore sequencing opens "new possibilities for clinical genomics" that weren't available before.

The initial phase will establish validation standards specific to Japan's healthcare system, ensuring the technology meets local requirements while maintaining the speed and accuracy that makes it valuable. As the partnership grows, it could accelerate genomic medicine development across the entire Asia-Pacific region.

When science crosses borders, everyone wins.